Treatment of severe hypertension during pregnancy: we still do not know what the best option is

Dagmar Wertaschnigg; Rui Wang; Maya Reddy; Fabricio Da Silva Costa; Ben Willem J. Mol; Daniel L. Rolnik

doi:10.1080/10641955.2019.1708383

Treatment of severe hypertension during pregnancy: we still do not know what the best option is

Dagmar Wertaschnigg^*, Rui Wang, Maya Reddy, Fabricio Da Silva Costa, Ben Willem J. Mol, Daniel L. Rolnik

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both–mother and fetus–is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians’ preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.

Original language	English
Pages (from-to)	25-32
Number of pages	8
Journal	Hypertension in Pregnancy
Volume	39
Issue number	1
Early online date	27 Dec 2019
DOIs	https://doi.org/10.1080/10641955.2019.1708383
Publication status	Published - 2 Jan 2020

Bibliographical note

DW is supported by a grant from the Paracelsus Medical University Salzburg, Austria (PMU Research Fund – PMU FFF Number: L-18/02/006-WET) and by Drs Haackert Foundation, Germany.

Keywords

key outcome parameters
maternal and perinatal morbidity
pre-eclampsia
Severe hypertension in pregnancy
target blood pressure
DIAGNOSIS
TRIALS
MANAGEMENT
SEVERE PREECLAMPSIA
GUIDELINES
DISORDERS
CLASSIFICATION
LABETALOL
HYDRALAZINE
NIFEDIPINE

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10641955.2019.1708383Licence: Unspecified

Cite this

@article{8a48dc1dbcff49af8e849d1c5424468c,

title = "Treatment of severe hypertension during pregnancy: we still do not know what the best option is",

abstract = "Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both–mother and fetus–is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians{\textquoteright} preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.",

keywords = "key outcome parameters, maternal and perinatal morbidity, pre-eclampsia, Severe hypertension in pregnancy, target blood pressure, DIAGNOSIS, TRIALS, MANAGEMENT, SEVERE PREECLAMPSIA, GUIDELINES, DISORDERS, CLASSIFICATION, LABETALOL, HYDRALAZINE, NIFEDIPINE",

author = "Dagmar Wertaschnigg and Rui Wang and Maya Reddy and Costa, {Fabricio Da Silva} and Mol, {Ben Willem J.} and Rolnik, {Daniel L.}",

note = "DW is supported by a grant from the Paracelsus Medical University Salzburg, Austria (PMU Research Fund – PMU FFF Number: L-18/02/006-WET) and by Drs Haackert Foundation, Germany. ",

year = "2020",

month = jan,

day = "2",

doi = "10.1080/10641955.2019.1708383",

language = "English",

volume = "39",

pages = "25--32",

journal = "Hypertension in Pregnancy",

issn = "1064-1955",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Treatment of severe hypertension during pregnancy

T2 - we still do not know what the best option is

AU - Wertaschnigg, Dagmar

AU - Wang, Rui

AU - Reddy, Maya

AU - Costa, Fabricio Da Silva

AU - Mol, Ben Willem J.

AU - Rolnik, Daniel L.

N1 - DW is supported by a grant from the Paracelsus Medical University Salzburg, Austria (PMU Research Fund – PMU FFF Number: L-18/02/006-WET) and by Drs Haackert Foundation, Germany.

PY - 2020/1/2

Y1 - 2020/1/2

N2 - Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both–mother and fetus–is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians’ preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.

AB - Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both–mother and fetus–is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians’ preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.

KW - key outcome parameters

KW - maternal and perinatal morbidity

KW - pre-eclampsia

KW - Severe hypertension in pregnancy

KW - target blood pressure

KW - DIAGNOSIS

KW - TRIALS

KW - MANAGEMENT

KW - SEVERE PREECLAMPSIA

KW - GUIDELINES

KW - DISORDERS

KW - CLASSIFICATION

KW - LABETALOL

KW - HYDRALAZINE

KW - NIFEDIPINE

UR - http://www.scopus.com/inward/record.url?scp=85077400128&partnerID=8YFLogxK

U2 - 10.1080/10641955.2019.1708383

DO - 10.1080/10641955.2019.1708383

M3 - Review article

C2 - 31880480

AN - SCOPUS:85077400128

SN - 1064-1955

VL - 39

SP - 25

EP - 32

JO - Hypertension in Pregnancy

JF - Hypertension in Pregnancy

IS - 1

ER -

Treatment of severe hypertension during pregnancy: we still do not know what the best option is

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this